NCT05252468 is a NA clinical trial of TaffiX™ in COVID-19, sponsored by Nasus Pharma.

Who is sponsoring NCT05252468?

NCT05252468 is sponsored by Nasus Pharma.

What drugs are being tested in NCT05252468?

Interventions in NCT05252468: TaffiX™.

What condition does NCT05252468 study?

NCT05252468 studies COVID-19, Upper Respiratory Tract Infections.

Is NCT05252468 still recruiting?

NCT05252468 is currently completed. Last updated 10 March 2022.

Last reviewed 2022-03-10 · How we verify

NCT05252468

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).

Completed NA Last updated 10 March 2022

What this trial tests

NA trial testing TaffiX™ in COVID-19 in 693 participants. Completed in 2 December 2021.

Timeline

19 May 2021

Primary endpoint
2 November 2021

2 December 2021

Quick facts

Lead sponsor	Nasus Pharma
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	693
Start date	19 May 2021
Primary completion	2 November 2021
Estimated completion	2 December 2021
Sites	1 location across Bulgaria

Drugs / interventions tested

TaffiX™

Conditions studied

COVID-19 — all drugs for COVID-19 →
Upper Respiratory Tract Infections — all drugs for Upper Respiratory Tract Infections →

Sponsor

Nasus Pharma — full company profile →

Who can join

Adults 12 to 120, any sex, with COVID-19 or Upper Respiratory Tract Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

TAFFIX is a nasal powder spray that immediately creates a protective acidic barrier on the nasal mucosa against infection by inhaled viruses. The protective barrier lasts 5 hours. TAFFIX is approved as a medical device in Israel, intended for use to block inhaled viruses within the nasal cavity. In Europe, it is registered as a medical device indicated for use as a protective mechanical barrier against allergens and viruses (e.g., SARS-CoV-2) within the nasal cavity. TAFFIX is used as additional safety mean together with masks, hygiene, and social distancing. The study rationale is to evaluate whether daily use of TaffiX™ as prophylaxis will reduce the rate of SARS- CoV-2 infection and other upper respiratory infections, compared to the placebo control rate.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Nasus Pharma trials

Trials by the same sponsor.

NCT07045701 — FMXIN002 in Patients at Risk of Anaphylaxis · Phase 2, PHASE3 · enrolling by invitation
NCT06205134 — Comparative Bioavailability of Intranasal Epinephrine · Phase 1, PHASE2 · completed
NCT04713709 — A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder · Phase 1 · completed
NCT04696822 — Bioavailability of Nasal Epinephrine · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05252468 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nasus Pharma
Last refreshed: 10 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05252468.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing